A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

Age Related Macular Degeneration Clinical Trial

— LAST  

Official title:

This is a Single-masked Study to Compare Intravitreally Administered 0.5 mg Ranibizumab to 2.0 mg Ranibizumab in Subjects Who Manifest Persistent or Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01115556
• Other study ID #: FVF4836S
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: May 2010
• Est. completion date: January 2012

Study information

• Verified date: May 2018
• Source: Vitreous -Retina- Macula Consultants of New York
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-masked study to compare intravitreally administered 0.5 mg ranibizumab to 2.0 mg ranibizumab in subjects who manifest persistent or recurrent macular fluid less than 30 days following treatment with intravitreal anti-VEGF therapy. Patients will be masked to their treatment assignment.

The study duration is anticipated to be 12 months and will enroll 30 subjects . Patients will be randomized 2:1 to either 2.0 mg ranibizumab or 0.5mg ranibizumab.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

Subjects will be eligible if the following criteria are met:

• Ability to provide written informed consent and comply with study assessments for the full duration of the study

• Age > 50 years

• Subfoveal neovascularization secondary to AMD

• Best corrected visual acuity in the study eye between 20/30 to 20/400 using an ETDRS chart

• Documentation of the presence of subretinal fluid and/or cystoid macular edema on SD-OCT less than 30 days following at least six months of anti-VEGF therapy

• Presence of fibrosis, hemorrhage, or other hypofluorescent lesions should not obscure greater than 50% of the CNV lesion

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from this study:

• Pregnancy (positive pregnancy test) or lactation

• Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

• Participation in another simultaneous medical investigation or trial

• Prior treatment with anti-VEGF therapy in the study eye within 30 days of BSL

• Prior treatment with triamcinolone in the study eye within 6 months of BSL.

• Prior treatment with dexamethasone in the study eye within 30 days prior to BSL

• Past treatment with PDT or thermal laser in the study eye

• Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding BSL

• History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye

• Active intraocular inflammation (grade trace or above) in the study eye

• Current vitreous hemorrhage in the study eye

• History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye

• Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye

• Uncontrolled glaucoma in the study eye (defined as IOP = 30 mmHg despite treatment with anti-glaucoma medication)

• History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment.

• History of allergy to fluorescein, not amenable to treatment

Related Conditions & MeSH terms

• Age Related Macular Degeneration
• Macular Degeneration

Intervention

Drug:
• Ranibizumab
2.0 mg
• Ranibizumab
0.5 mg

Locations

Country	Name	City	State
United States	Vitreous Retina Macula Consultants of New York	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Vitreous -Retina- Macula Consultants of New York	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change in Visual Acuity (VA) From Baseline at Month 6		Baseline and 6 months
Secondary	Mean Change in Visual Acuity (VA) From Baseline at Month 12	Mean change in Visual Acuity (VA) from Baseline at Month 12; Mean change in central foveal thickness (RPE to ILM) as measured by SD-OCT (Spectralis HRA + OCT (Heidelberg Engineering, Heidelberg, Germany) at Months 6 and 12; Mean change in leakage as determined by FA at Months 6 and 12; Mean number of ranibizumab injections at Months 6 and 12; Mean time to first re-treatment following the initial 3 monthly loading doses; Mean duration of fluid-free interval; Safety and tolerability of 2.0mg using the incidence and severity of adverse events	one year